Itracibra 100 Capsule contains Itraconazole 100 mg, a broad-spectrum triazole antifungal agent used for the treatment of various systemic and superficial fungal infections. Itraconazole acts by inhibiting the synthesis of ergosterol, an essential component of fungal cell membranes, thereby disrupting membrane integrity and leading to fungal cell death. It is indicated for the management of infections such as aspergillosis, blastomycosis, histoplasmosis, onychomycosis, and candidiasis, including oropharyngeal and esophageal candidiasis. Itracibra 100 Capsule is administered orally and exhibits good bioavailability when taken with food, enhancing its absorption. The drug is metabolized primarily in the liver via the cytochrome P450 system, necessitating caution in patients with hepatic impairment and potential drug interactions. Common adverse effects include gastrointestinal disturbances, headache, and rash, while rare but serious effects may involve hepatotoxicity and congestive heart failure exacerbation. Monitoring liver function tests during prolonged therapy is recommended. Itracibra 100 Capsule should be prescribed with consideration of patient-specific factors and contraindications, including hypersensitivity to itraconazole or other azole antifungals. This medication requires a healthcare professional’s supervision to ensure efficacy and safety in the treatment of fungal infections.